Adding the "medicines' back into personalized medicine to improve cancer treatment outcomes

被引：3
|
作者：
Martin, Jennifer H. [1 ,2 ]
Phillips, Elizabeth [3 ,4 ]
Thomas, David [5 ,6 ]
Somogyi, Andrew A. [7 ,8 ]
机构：
[1] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia
[2] Univ Queensland, Diamantina Inst, Woolloongabba, Qld, Australia
[3] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[4] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia
[5] St Vincents Hosp, Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia
[6] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW 2052, Australia
[7] Univ Adelaide, Fac Hlth Sci, Discipline Pharmacol, Adelaide, SA 5001, Australia
[8] Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA 5000, Australia
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2015年 / 80卷 / 05期
关键词：
CELL LUNG-CANCER; INHIBITION; ABACAVIR; KINASE; TUMORS;
D O I：
10.1111/bcp.12690
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：929 / 931
页数：3
相关论文
共 50 条
  • [41] Implications of personalized medicine-perspective from a cancer center
    Tursz, Thomas
    Andre, Fabrice
    Lazar, Vladimir
    Lacroix, Ludovic
    Soria, Jean-Charles
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (03) : 177 - 183
  • [42] Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists
    O'Neill, Ailbhe C.
    Jagannathan, Jyothi P.
    Ramaiya, Nikhil H.
    KOREAN JOURNAL OF RADIOLOGY, 2017, 18 (01) : 6 - 17
  • [43] Innovative personalized medicine in gastric cancer: time to move forward
    Lee, J.
    Kim, K. -M.
    Kang, W. K.
    Ou, S. -H. I.
    CLINICAL GENETICS, 2014, 86 (01) : 37 - 43
  • [44] Microsatellite instability and cancer: from genomic instability to personalized medicine
    Collura, Ada
    Lefevre, Jeremie H.
    Svrcek, Magali
    Tougeron, David
    Zaanan, Aziz
    Duval, Alex
    M S-MEDECINE SCIENCES, 2019, 35 (6-7): : 535 - 543
  • [45] Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?
    Cirkel, Geert A.
    Gadellaa-van Hooijdonk, Christa G.
    Koudijs, Marco J.
    Willems, Stefan M.
    Voest, Emile E.
    FUTURE ONCOLOGY, 2014, 10 (03) : 417 - 428
  • [46] Predictive biomarkers: a paradigm shift towards personalized cancer medicine
    La Thangue, Nicholas B.
    Kerr, David J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (10) : 587 - 596
  • [47] Understanding serine and glycine metabolism in cancer: a path towards precision medicine to improve patient's outcomes
    Sanchez-Castillo, Anais
    Kampen, Kim R.
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [48] Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes
    Shulman, Lawrence N.
    Wagner, Claire M.
    Barr, Ronald
    Lopes, Gilberto
    Longo, Giuseppe
    Robertson, Jane
    Forte, Gilles
    Torode, Julie
    Magrini, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (01) : 69 - +
  • [49] Hotspot oncomutations: implications for personalized cancer treatment
    Myers, Meagan B.
    Wang, Yiying
    Mckim, Karen L.
    Parsons, Barbara L.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2012, 12 (06) : 603 - 620
  • [50] Pancreatic cancer: BRCA mutation and personalized treatment
    Luo, Guopei
    Lu, Yu
    Jin, Kaizhou
    Cheng, He
    Guo, Meng
    Liu, Zuqiang
    Long, Jiang
    Liu, Chen
    Ni, Quanxing
    Yu, Xianjun
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (10) : 1223 - 1231
12345